Overview
TMVP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer
Status:
Unknown status
Unknown status
Trial end date:
2019-05-01
2019-05-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Sentinel lymph node (SLN) mapping is an acceptable surgical strategy determine whether to perform radical lymphadenectomy in patients with early-stage cervical cancer. Investigators aim to determine the validity of this technique with our novel tumor targeted fluorescent TMVP1-ICG to increased accuracy of SLN mapping.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Huazhong University of Science and Technology
Criteria
Inclusion Criteria:- At least 18 years of age, married, without childbearing requirements at the time of
consent.
- FIGO stage IA1-IIB cervical squamous cell cancer and is a candidate for laparoscopy
intervention, with lymph node dissection being a part of the surgical plan.
- Subject has provided written informed consent.
Exclusion Criteria:
- Breast-feeding or pregnant
- Ongoing participation in another clinical trial with an investigational drug with 3
months
- Own allergy towards ICG and/or alcohol
- Diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases
- Patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency